Skip to main content
Medicover logo

Medicover — Investor Relations & Filings

Ticker · MCOV ISIN · SE0009778848 LEI · 5493000E9BUOYMOW2K53 ST Human health and social work activities
Open in API
Filings indexed 285 across all filing types
Latest filing 2025-02-12 Earnings Release
Country SE Sweden
Listing ST MCOV

About Medicover

https://www.medicover.com/

Medicover is an international healthcare and diagnostic services provider. The company operates through two main divisions: Healthcare Services and Diagnostic Services. The Healthcare Services division delivers a broad range of medical care, including primary care, specialist consultations, and hospital treatment. The Diagnostic Services division offers a comprehensive array of laboratory tests, from routine to advanced diagnostics, serving a wide network of clients. Committed to patient-centric care, Medicover focuses on quality, accessibility, and affordability by investing in modern medical technology and innovation. Its core mission is to improve and sustain the health and wellbeing of its customers.

Recent filings

Filing Released Lang Actions
Earnings Release 2024
Earnings Release Classification · 1% confidence The document is titled "BOKSLUTSKOMMUNIKÉ JANUARI–DECEMBER 2024" (Year-End Report Communication January–December 2024) and provides detailed financial results for the Fourth Quarter and the Full Year (Helår) 2024, including key metrics like Revenue, EBIT, Net Income, EBITDA, and EPS, comparing them to 2023. It also includes a CEO's statement (VD-ORD) discussing performance, strategic outlook, and future financial targets for 2025. This structure—comprehensive annual financial summary with management commentary—is characteristic of an Annual Report or a detailed Earnings Release that often precedes or substitutes for the full 10-K filing in non-US contexts, or a comprehensive Interim/Quarterly Report if the period was shorter. Since it covers the full year (Januari–December) and presents the final year-end figures, it aligns best with the comprehensive nature of an Annual Report (10-K equivalent) or a detailed year-end report. Given the depth of financial data and the year-end focus, it is classified as an Annual Report (10-K), although it is presented in a press release/communication format rather than the formal SEC filing itself. However, since the definitions provided do not explicitly cover 'Year-End Financial Communication' but do cover 'Annual Report (10-K)' for full yearly performance, and this document contains the full yearly performance, 10-K is the closest fit for comprehensive annual results. FY 2024
2025-02-12 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Year-End Report' for the period January–December 2024, containing comprehensive financial statements, segment analysis, CEO commentary, and operational metrics. It provides detailed financial data for both the fourth quarter and the full fiscal year. It is not an announcement of a report (RPA) nor a simple earnings release (ER), as it contains substantive financial analysis and detailed performance data. Therefore, it is classified as an Interim/Quarterly Report (IR), which covers periodic financial reporting for periods shorter than a full fiscal year or, in this case, a year-end report that functions as the comprehensive financial disclosure for the period. Q4 2024
2025-02-12 English
John Stubbington utsedd till ny vd för Medicover från och med 1 maj 2025
Board/Management Information Classification · 1% confidence The document is a press release dated February 12, 2025, announcing a change in the CEO of Medicover AB. Specifically, it states that John Stubbington will succeed Fredrik Rågmark as CEO starting May 1, 2025. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and serves as an announcement, not a comprehensive report.
2025-02-12 Swedish
John Stubbington appointed new CEO of Medicover from 1 May 2025
Board/Management Information Classification · 1% confidence The document is a press release dated February 12, 2025, announcing a change in senior management: John Stubbington is appointed as the new CEO, succeeding Fredrik Rågmark. This directly aligns with the definition of 'Board/Management Information' (Code: MANG), which covers the announcement of changes in the company's board of directors or senior management. The document is short and clearly an announcement, not a comprehensive report.
2025-02-12 English
Medicover to evaluate a potential separate listing in india
Regulatory Filings Classification · 1% confidence The document is a short press release announcing the board of directors' decision to evaluate a potential separate listing (IPO) of its Indian hospital subsidiary in India. This action relates to corporate structure, financing strategy, and potential capital market activities. It is not a full financial report (10-K, IR), an earnings release (ER), or a standard regulatory filing (RNS). The core subject is a strategic corporate action involving capital structure/fundraising potential. This aligns best with the 'Capital/Financing Update' category (CAP), as it discusses a potential future listing/fundraising event, or potentially 'Regulatory Filings' (RNS) if it were purely an announcement mandated by market abuse rules without a clear strategic focus. Given the focus on a 'potential separate listing' to 'support its growth ambitions,' CAP is the most specific fit, as it deals with capital structure changes/fundraising evaluation. The document length is short, but it is the primary announcement itself, not just an announcement *of* an attached report.
2024-12-10 English
Medicover utvärderar en potentiell separat börsnotering av det indiska sjukhusdotterbolaget i Indien
M&A Activity Classification · 1% confidence The document is a press release dated December 10, 2024, announcing that the Board of Directors of Medicover AB has decided to evaluate a potential separate stock market listing (IPO) for its Indian hospital subsidiary. This action relates to corporate structure, financing, and potential capital market activities concerning a major business unit. This fits best under 'Capital/Financing Update' (CAP) as it discusses a major structural change involving fundraising/listing, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the specific nature of evaluating a listing to support growth ambitions, CAP is the most precise fit over the general RNS fallback. The document is short and is an announcement, not the final prospectus or detailed financing document.
2024-12-10 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.